Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 43, n° 4
pages 708-711 (octobre 2000)
Doi : 10.1067/mjd.2000.107500
The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: The need for more evidence

Arash Kimyai-Asadi, MD a, Adil Usman, MD b
a Ronald O. Perelman Department of Dermatology, The New York University School of Medicine New York, New York 
b Department of Dermatology, The Columbia University College of Physicians and Surgeons. New York, New York 


Interferon alfa is rapidly gaining acceptance as the standard of care for patients with advanced but nonmetastatic cutaneous malignant melanoma. The randomized trials of interferons for melanoma are reviewed with attention to any survival benefits demonstrated by these studies. Because none of these studies are placebo controlled, questions regarding the placebo effects interferons may possess are addressed, as is an analogous clinical scenario in which interferons appeared to be beneficial in nonplacebo controlled trials but were shown to be ineffective in placebo-controlled trials. Moreover, given the significant toxicities and financial costs of interferons, the argument is advanced that interferon alfa should not become the standard of care for melanomas until the results of randomized, placebo-controlled trials evaluating the survival advantages of interferon alfa for melanoma become available. (J Am Acad Dermatol 2000;43:708-11.)

The full text of this article is available in PDF format.

 J Am Acad Dermatol 2000;43:708-11.
 Reprint requests: Arash Kimyai-Asadi, MD, The Ronald O. Perelman Department of Dermatology, The New York University School of Medicine, 401 E 34th St, S-6N, New York, NY 10016.

Top of the page

© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline